Avance Clinical Named Frost & Sullivan’s 2026 Global Biotechnology CRO of the Year

• Avance Clinical has been awarded the 2026 Global Company of the Year Recognition in the biotechnology CRO industry by Frost & Sullivan, recognizing outstanding achievement in innovation, strategy execution, and customer impact across its biotech-focused clinical development model.

• The recognition highlights Avance Clinical’s GlobalReady model, its expansion of Centers of Excellence in oncology, CNS, and cardiometabolic research, and its use of Australia’s regulatory and cost advantages to accelerate sponsor timelines across Phase I through later-stage trials.

Avance Clinical has been awarded the 2026 Global Company of the Year Recognition in the biotechnology CRO industry by Frost & Sullivan, following a rigorous benchmarking evaluation across strategy effectiveness and strategy execution. The recognition, announced May 12, 2026, positions Avance Clinical as the leading CRO for biotech sponsors operating in an increasingly competitive and complex clinical development landscape.

Frost & Sullivan evaluated Avance Clinical on its ability to align closely with biotech sponsor needs while executing with speed, precision, and scalability. The firm’s assessment cited the company’s biotech specialization, its GlobalReady model enabling seamless progression from Phase I through later-phase trials across the United States, Asia-Pacific, and Europe, and its investment in advanced analytics and AI-enabled data systems as core differentiators. “Avance Clinical stands out for its ability to align deeply with the unique pressures of biotech development, combining scientific rigor, operational agility, and continuity across clinical phases to deliver measurable progress for sponsors,” said Unmesh Lal, Vice President at Frost & Sullivan.

For biotech sponsors, Avance Clinical’s model is structured around continuity and transparency rather than transactional engagement. The company embeds senior leadership directly into project teams, maintains consistent personnel across studies, and tailors delivery models to individual sponsor needs. This approach is designed to reduce the friction that typically arises from funding pressure, regulatory complexity, and the need to accelerate development timelines simultaneously. Established Centers of Excellence in oncology, CNS, and cardiometabolic research further strengthen the company’s ability to support complex, high-value programs from early through late phase.

Australia remains a strategic anchor of the Avance Clinical CRO model. Rapid study start-up timelines, cost efficiencies relative to other major clinical markets, and a favorable regulatory environment allow biotech sponsors to generate globally accepted Phase I data at pace. These advantages are reinforced by Avance Clinical’s 30 years of experience across more than 250 indications and its expanded presence in Australia, New Zealand, Asia, North America, the UK, and Europe.

“We are honored to receive Frost & Sullivan’s 2026 Global Biotechnology CRO of the Year Recognition, reflecting the strength of our team and our commitment to advancing biotech innovation. This recognition highlights our ability to help our biotech clients accelerate timelines with our focus and strength in Australia, coupled with our global operations to power patient enrollment for later phase studies.”

Mark Harvill, Chief Executive Officer, Avance Clinical